Detalhe da pesquisa
1.
Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease.
Blood
; 141(15): 1817-1830, 2023 04 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36706355
2.
Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study.
Cancer
; 130(6): 985-994, 2024 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37962072
3.
Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment.
Cancer Immunol Immunother
; 73(1): 17, 2024 Jan 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38236249
4.
Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation.
Blood
; 137(23): 3212-3217, 2021 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33720354
5.
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol
; 23(2): 279-291, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35033226
6.
Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males.
J Transl Med
; 20(1): 253, 2022 06 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35659704
7.
A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation.
Blood
; 135(24): 2182-2191, 2020 06 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32478814
8.
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings.
Blood
; 141(15): 1884-1888, 2023 04 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36332187
9.
Ipilimumab for Patients with Relapse after Allogeneic Transplantation.
N Engl J Med
; 375(2): 143-53, 2016 Jul 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-27410923
10.
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
Lancet Oncol
; 19(3): 416-426, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29370992
11.
First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile.
Invest New Drugs
; 36(2): 230-239, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28808818
12.
Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study.
Lancet Oncol
; 18(4): 446-453, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28223062
13.
Checking up on checkpoint inhibitors.
Blood
; 130(2): 107-108, 2017 07 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-28705859
14.
Immune checkpoint inhibitors in clinical trials.
Chin J Cancer
; 33(9): 434-44, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25189716
15.
Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial.
J Natl Cancer Inst
; 2024 Jan 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38243705
16.
Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial.
Nat Cancer
; 2024 Feb 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38355777
17.
Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers.
J Clin Oncol
; 42(9): 1011-1020, 2024 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38252910
18.
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.
J Clin Oncol
; 41(2): 186-197, 2023 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36166727
19.
Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors.
J Immunother Cancer
; 10(3)2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35264434
20.
Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary.
J Immunother Cancer
; 10(1)2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35074904